دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S0039-6257(23)00029-2
Volume 68, Issue 2, March–April 2023, Pages A2-A3
Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods
Osama A. Sorour, MD, FRCS(Glasg) a,b, Emily S. Levine, MTM a,c, Caroline R. Baumal, MD a, Ayman G. Elnahry, MD, PhD d, Phillip Braun, MD a, Jessica Girgis, BS a, Nadia K. Waheed, MD, MPH
doi : 10.1016/j.survophthal.2022.11.008
Volume 68, Issue 2, March–April 2023, Pages 147-174
Intravitreal antivascular endothelial growth factor (anti-VEGF) treatment has drastically improved the visual and anatomical outcomes in patients with diabetic macular edema (DME); however, success is not always guaranteed, and a proportion of these eyes demonstrate persistent DME (pDME) despite intensive treatment.
Retinopathy of prematurity: A review of pathophysiology and signaling pathways
Mariza Fevereiro-Martins, MD a,b,c,∗, Carlos Marques-Neves, MD, PhD d,e, HercÃlia Guimarães, MD, PhD f, Manuel Bicho, MD, PhD
doi : 10.1016/j.survophthal.2022.11.007
Volume 68, Issue 2, March–April 2023, Pages 175-210
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina and a leading cause of visual impairment and childhood blindness worldwide. The disease is characterized by an early stage of retinal microvascular degeneration, followed by neovascularization that can lead to subsequent retinal detachment and permanent visual loss.
Laser treatment for choroidal melanoma: Current concepts
Abhilasha Maheshwari, MD∗, Paul T. Finger, MD
doi : 10.1016/j.survophthal.2022.05.002
Volume 68, Issue 2, March–April 2023, Pages 211-224
Laser treatment has offered a relatively nonsurgical alternative for eye, life, and vision-sparing treatment of malignant melanoma of the choroid. Historically, the most commonly used forms of lasers were xenon-arc, argon laser, krypton laser, and the more recent transpupillary thermotherapy (TTT) and photodynamic therapy (PDT).
A review of patient-reported outcome measures used in uveitis
Mallika Prem Senthil, PhD a,∗, Sumu Simon, FRANZCO b, Paul A. Constable, PhD
doi : 10.1016/j.survophthal.2022.11.004
Volume 68, Issue 2, March–April 2023, Pages 225-240
We review patient-reported outcome measures (PROMs) used to evaluate the quality of life (QoL) in uveitis and provide a quality assessment of the psychometric properties of the PROMs, making it easier to choose the best questionnaire for uveitis. Our review included 158 articles.
Anti-tubercular therapy in the treatment of tubercular uveitis: A systematic review and meta-analysis
Bjorn Kaijun Betzler, MBBS a, Ikhwanuliman Putera, MD b,c, Ilaria Testi, MD d, Rina La Distia Nora, PhD b,c, John Kempen, PhD e,f,g, Onn Min Kon, MD h, Carlos Pavesio, FRCOphth d, Vishali Gupta, MD i, Rupesh Agrawal, FRCS
doi : 10.1016/j.survophthal.2022.10.001
Volume 68, Issue 2, March–April 2023, Pages 241-256
We quantitatively evaluated the efficacy of antitubercular therapy (ATT) in tubercular uveitis (TBU) patients. Main outcome measures include inflammation recurrence, inflammation reduction, complete resolution of inflammation, improved visual acuity (VA), ability to taper corticosteroids to < 10 mg/day without inflammatory progression, and use of adjunctive immunosuppressants while on ATT.
Association between obstructive sleep apnea and floppy eyelid syndrome: A systematic review and metaanalysis
Alex Jia Yang Cheong a,#, Owen Tsung Wen Ho a,#, Sean Kang Xuan Wang a, Chang Yi Woon a, Kihan Yap a, Kevin Joo Yang Ng a, Flora Wen Xin Xu a, Anna See, MD a,b,f,g, Adele Chin Wei Ng, MD b,g, Shaun Ray Han Loh, MD a,b,c,f,g, Soon-Phaik Chee, MD a,d,e,f, Song Tar Toh, MD
doi : 10.1016/j.survophthal.2022.11.006
Volume 68, Issue 2, March–April 2023, Pages 257-264
Obstructive sleep apnoea (OSA) has been linked to various ocular disorders, including floppy eyelid syndrome (FES). Previous studies have hypothesised the underlying association between the 2 , but results are currently still inconclusive.
The transconjunctival orbitotomy: A versatile approach to the orbit and beyond
Ilse Mombaerts, MD, PhD a,b,∗, Richard C. Allen, MD, PhD, FACS c
doi : 10.1016/j.survophthal.2022.11.003
Volume 68, Issue 2, March–April 2023, Pages 265-279
In the management of orbital disorders and defects, minimally invasive surgical approaches have become increasingly efficient for their reduction of operative trauma and access without compromise of therapeutic benefit or diagnostic yield.
The inflammasome pathway: A key player in ocular surface and anterior segment diseases
Jordan T. Mandell, BS a, Juan Pablo de Rivero Vaccari, PhD, MSBA b, Alfonso L. Sabater, MD, PhD c, Anat Galor, MD, MSPH
doi : 10.1016/j.survophthal.2022.06.003
Volume 68, Issue 2, March–April 2023, Pages 280-289
Inflammasomes are multicomplex molecular regulators with an emerging importance in regulating ocular surface and anterior segment health and disease.
Ocular manifestations in IgA nephropathy
Hnin Hnin Oo, MMed a, Mun Yoong Darren Choy, MMed a, Atul Arora, MD b, See Cheng Yeo, MBBS, MMed, FRCP (London) c,g,h, Raja Ramachandran, MD d, Vishali Gupta, MD b, Peter McCluskey, PhD e,∗∗, Rupesh Agrawal, MD, MMed, FRCS, MMed, MBBS, Professor
doi : 10.1016/j.survophthal.2022.09.004
Volume 68, Issue 2, March–April 2023, Pages 290-307
Immunoglobulin A nephropathy (IgAN) is a rare but important systemic disease with or without ocular manifestations. We describe 4 cases of IgAN presenting with scleritis and review the various ocular manifestations in patients with IgAN.
Skin in the game
Michael S. Vaphiades, DO a,∗, Brendan Grondines, COA a, Lanning B. Kline, MD a, Emily Riser, MD a, Doran Spencer, MD, PhD
doi : 10.1016/j.survophthal.2021.11.004
Volume 68, Issue 2, March–April 2023, Pages 308-311
A 23-year-old man with a history of migraine and focal seizures, developed painless visual loss in the left eye associated with optic disk edema. There was no recent history of cat exposure except for a cat that lives outside.
